Pfizer, Sanofi-backed LNP outfit goes back to the well and draws $120M for its trek to the clinic

A preclinical biotech touting a five-lipid drug delivery platform is looking to break out of its preclinical mold, and it just secured a sizable raise to do just that.

ReCode Therapeutics reported Wednesday morning that Leaps by Bayer and Matrix Capital Management affiliate AyurMaya co-led a Series B extension round,...

Click to view original post